Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein
Walker, L. M.; Wec, A. Z.; Wrap, D.; Herbert, A. S.; Maurer, D. P.; Haslwanter, D.; Sakharkar, M.; Jangra, R. K.; Dieterle, M. E.; Lilov, A.; Huang, D.; Tse, L. V.; Johnson, N. V.; Hsieh, C.-L.; Wang, N.; Nett, J. H.; Champney, E.; Burnina, I.; Brown, M.; Lin, S.; Sinclair, M.; Johnson, C.; Pudi, S.; Bortz, R.; Wirchnianski, A. S.; Laudermilch, E.; Florez, C.; Fels, J. M.; O'Brien, C. M.; Graham, B. S.; Nemazee, D.; Burton, D. R.; Baric, R. S.; Voss, J. E.; Chandran, K.; Dye, J. M.; McLellan, J. S.
Show abstract
Broadly protective vaccines against known and pre-emergent coronaviruses are urgently needed. Critical to their development is a deeper understanding of cross-neutralizing antibody responses induced by natural human coronavirus (HCoV) infections. Here, we mined the memory B cell repertoire of a convalescent SARS donor and identified 200 SARS-CoV-2 binding antibodies that target multiple conserved sites on the spike (S) protein. A large proportion of the antibodies display high levels of somatic hypermutation and cross-react with circulating HCoVs, suggesting recall of pre-existing memory B cells (MBCs) elicited by prior HCoV infections. Several antibodies potently cross-neutralize SARS-CoV, SARS-CoV-2, and the bat SARS-like virus WIV1 by blocking receptor attachment and inducing S1 shedding. These antibodies represent promising candidates for therapeutic intervention and reveal a new target for the rational design of pan-sarbecovirus vaccines.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- High-affinity, neutralizing antibodies to SARS-CoV-2 can be made in the absence of T follicular helper cells 98%
- CD4-binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals 96%
- Differential antibody dynamics to SARS-CoV-2 infection and vaccination 96%
Similar papers in this journal
Similar papers in this journal
- Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease 97%
- A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants 97%
- A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope 96%
Similar papers in this journal
- Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques 98%
- A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection 97%
- The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD 97%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.